Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem Cell Therapeutics Bags US Patent
The claims covers the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to
The claims covers the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to
The trial established the pharmacokinetics of the protein and demonstrated that single dose, intravenous administration of PRX-105 is safe and well tolerated. Protalix plans to perform additional safety
Nautilus claimed that, Cambia, a novel, water-soluble, buffered diclofenac potassium powder, is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Cambia is
Renhuang Pharma has posted a net income of $3.4m, or $0.09 per diluted share, compared to $2.09m, or $0.06 per diluted share, for the prior year period. Income
Management believes SOHM India’s manufacturing infrastructure is in place to grow sales of its private label generic pharmaceutical and nutraceutical product lines. Shailesh Shah, vice president for corporate
Opal Therapeutics is an immunotherapy development company focusing on novel therapies for HIV and Hepatitis C (HCV) based on proprietary technology licensed from the University of Melbourne. The
AMG 386 is an investigational peptibody that is designed to block angiogenesis by inhibiting angiopoietin-1 and -2 (Ang1 and Ang2). In the Amgen’s study patients were randomised to
Roche said that the study known as GOG 0218, was conducted by a network of researchers led by the Gynecologic Oncology Group (GOG). Roche’s GOG 0218 study demonstrated
Sprycel, an oral BCR-ABL inhibitor, is currently approved by the FDA for the treatment of adults for all phases of CML (chronic, accelerated, or myeloid or lymphoid blast
Ascenta Therapeutics and sanofi-aventis said that these orally-active, small-molecule drug candidates remove a block to normal p53 tumor suppressor function and inhibit the interaction between HDM2 (Human Double